StockWatch
·
Q2 FY-2027 RESULTS · GUFICBIO

Gufic Q2: consolidated PAT +40% YoY to ₹23.5 Cr, revenue +22%, but misses ₹35-42 Cr bar

PAT +39.51% YoY · revenue +21.6% · margins expanding · miss vs street

Q2 FY27 resultsGUFICBIOGUFIC BIOSCIENCES LTD.14 Nov 2026 · 3 min read
Revenue

₹288.27 Cr

+21.6% YoY

PAT (consolidated)

₹23.47 Cr

+39.51% YoY

Net margin

8.11%

+1.1pp YoY

EPS

₹2.34

Gufic's consolidated revenue came in at ₹288.27 Cr, up 21.6% YoY and 10.5% QoQ, while consolidated PAT rose 39.5% YoY to ₹23.47 Cr but grew just 5.2% QoQ from ₹22.31 Cr — a clear sequential slowdown in profit growth even as the topline accelerated. Standalone PAT of ₹23.49 Cr grew a faster 57.2% YoY (from ₹14.94 Cr a year ago), a meaningfully wider gap than the consolidated 39.5% YoY print: a year ago the foreign/CMO subsidiaries (Gufic UK, Veira Life FZE, Gufic Ireland, Gufic Prime) added roughly ₹2 Cr of incremental profit over standalone, but this quarter their net contribution to the group turned marginally negative versus standalone — the subsidiaries that boosted consolidated growth last year are now a mild drag on it.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹288.27 Cr+10.5%+21.6%
Expenses₹257.95 Cr+11.6%+19.1%
PAT₹23.47 Cr+5.18%+39.51%
Net margin8.11%-0.4pp+1.1pp
EPS₹2.34+5.4%+39.3%

Operating margin expanded YoY to 16.82% from 15.97%, and net margin to 8.11% from 7.03%, but both compressed sequentially from Q1's 17.87% OPM / 8.54% NPM. The QoQ squeeze traces to cost of materials consumed jumping 47.9% QoQ (₹156.92 Cr vs ₹106.14 Cr) against only 10.5% QoQ revenue growth — materials cost outran the topline this quarter even though the YoY margin comparison still looks favourable against a weaker year-ago base.

₹
376.13406.8437.48468.15498.82473.0508-1109-0209-2510-2111-1211-13
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹473.05, up 13.6% over the past month of trading.

₹ Cr
08.7617.5226.2813.07Q1 FY26rev ₹224 Cr16.82Q2 FY26rev ₹237 Cr12.42Q3 FY26rev ₹231 Cr21.9Q4 FY26rev ₹252 Cr22.31Q1 FY27rev ₹261 Cr23.47Q2 FY27rev ₹288 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.

What management guided (1 FY-2027 call)
FY27 full-year revenue ₹1,100 Cr baseline with 15% growth potential reaching ₹1,250-1,600 Cr. EBITDA margins ~18% in FY27, targeting >20% by 2030 through Indore utilization (40-45% by year-end), CMO ramp-up (30% domestic, 70% international mix), and product mix improvement. Capex ~₹300 Cr absorbed.

— This quarter: met

No formal analyst consensus for this specific quarter turned up in a search, so the cleanest expectation check is our own pre-result preview: it flagged revenue of ~₹260-280 Cr and PAT of ₹35-42 Cr. Actual revenue (₹288.27 Cr) cleared that range, but PAT (₹23.47 Cr) missed the low end by roughly a third — a beat on the top line paired with a sizeable miss on profitability. Against management's standing FY27 guidance (₹1,100 Cr baseline revenue with 15% upside to ₹1,250-1,600 Cr, ~18% operating margin), H1 FY27 consolidated revenue of ₹550.67 Cr annualises to ~₹1,101 Cr — right on the baseline but showing no sign yet of the double-digit upside case — while H1 OPM of 17.32% (and this quarter's 16.82%) still trails the ~18% target, with the Indore capacity ramp management has cited as the lever to close that gap not yet fully reflected. No company press release was available in our records to cross-check management's own framing of the quarter.

  • W1

    H2 FY27 margin trajectory — can OPM recover toward management's ~18% FY27 target as Indore utilization ramps toward the flagged 40-45% by year-end?

  • W2

    Remediation/resolution of the 3 USFDA observations from the Oct 15-23 pre-approval inspection, and its bearing on the flagged product's US approval timeline

  • W3

    Whether H2 revenue accelerates enough to move beyond the ₹1,100 Cr FY27 baseline run-rate toward management's ₹1,250-1,600 Cr upside case

Text-based filing, clean column headers (Standalone+Consolidated x Q2/Q1/Q2-ago/H1/H1-ago/FY); no exceptional items in current or comparison periods; minority interest negligible (₹0.03 Lakh); figures converted from Rs. Lakhs to Rs. Crore (÷100). Consolidated PAT uses 'net profit from continuing operations' line (pre-minority) for consistency with comparison-context figures.

Informational and educational content only. Not investment advice.